Open in App
  • U.S.
  • Election
  • Newsletter
  • Reuters

    Blackstone selling Japan drugmaker Alinamin to MBK Partners

    By Reuters,

    19 days ago
    https://img.particlenews.com/image.php?url=4XJIBC_0uCbIMTq00

    TOKYO (Reuters) - Blackstone and MBK Partners said on Wednesday the U.S. private equity firm is selling Japanese drugmaker Alinamin Pharmaceutical to the North Asian buyout fund.

    The deal size would be 350 billion yen ($2.17 billion), a source said on Tuesday, however neither Blackstone nor MBK in their separate statements disclosed the transaction value.

    Blackstone acquired Alinamin in 2020 from Takeda Pharmaceutical in what it said was the largest healthcare transaction in Japan.

    Blackstone will re-invest an indirect, minority stake in Alinamin upon the closing of the transaction, it said.

    ($1 = 161.5100 yen)

    (Reporting by Anton Bridge; Editing by Muralikumar Anantharaman)

    Expand All
    Comments / 0
    Add a Comment
    YOU MAY ALSO LIKE
    Most Popular newsMost Popular

    Comments / 0